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In recent years, researchers have attempted to use gene- and cell-based therapies to restore 
dystrophin and alleviate the muscle weakness that results from Duchenne muscular dystrophy 
(DMD). Our research group has isolated a population of muscle-derived stem cells (MDSCs) 
from the postnatal skeletal muscle of mice. In comparison with satellite cells, MDSCs display an 
improved transplantation capacity in dystrophic mdx muscle that can be attributed to their ability 
to undergo long-term proliferation, self-renewal, and multipotent differentiation, including 
differentiation toward endothelial and neuronal lineages. The overall goal of this study was to 
investigate whether the use of nerve growth factor (NGF) improves the transplantation efficiency 
of MDSCs. Two methods of in vitro NGF stimulation were used: retroviral transduction of 
MDSCs with a CLNGF vector to constitutively express NGF and direct stimulation of MDSCs 
with NGF protein. Neither method of NGF treatment changed the marker profile or proliferation 
behavior of the MDSCs, but direct stimulation with NGF protein significantly delayed cells’ in 
vitro differentiation ability. Stimulation with NGF also significantly enhanced the engraftment 
efficiency of MDSCs transplanted within the dystrophic muscle of mdx mice, resulting in better 
muscle regeneration. These findings highlight the importance of NGF as a modulatory molecule, 
the study of which will broaden our understanding of its biological role in the regeneration and 
repair of skeletal muscle by muscle-derived cells.  
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1.0 BACKGROUND 
 
 
 
 
1.1 ADULT SKELETAL MUSCLE CHARACTERISTICS 
 
 
The muscle fibers are the basic contractile units of skeletal muscles, individually surrounded by a 
connective tissue layer and grouped into bundles called perimysium to form a skeletal muscle 
(Figure 1.1A). Myofibers are multinucleated syncytia with their postmitotic myonuclei located at 
the periphery, as seen in the muscle cross-section stained with hematoxylin and eosin (H&E) 
(Figure 1.1B, arrow). As well as being rich in connective tissue, skeletal muscles are highly 
vascularized to provide essential nutrients for muscle function (Figure 1.1B, black arrowhead). 
As the myofiber matures, it is contacted by a single motor neuron that branches throughout the 
muscle (Figure 1.1B, white arrowhead). The functional properties of skeletal muscle including 
its contractile ability depend on the maintenance of a complex framework of myofibers, motor 
neurons, blood vessels, and extracellular connective tissue matrix. Therefore, revascularization, 
reinnervation, and reconstitution of the extracellular matrix are all essential aspects of the muscle 
regeneration process. 
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Figure 1.1 Morphological characteristics of adult mammalian skeletal muscle 
 
 
 
 
1.2 MORPHOLOGICAL CHARACTERISTICS OF SKELETAL MUSCLE 
REGENERATION 
 
 
Skeletal muscle is a heterogeneous tissue, containing vascular and neural cells in addition to the 
contractile myofibers. Adult mammalian skeletal muscle is a stable tissue with little turnover of 
nuclei [1, 2]. Minor lesions inflicted by day-to-day wear and tear elicit only a slow turnover of its 
constituent multinucleated muscle fibers. It is estimated that in a normal adult rat muscle, no 
more than 1–2% of myonuclei are replaced every week [2]. Nonetheless, mammalian skeletal 
muscle has the ability to complete a rapid and extensive regeneration in response to severe 
damage. Whether the muscle injury is inflicted by a direct trauma (i.e., extensive physical 
activity and especially resistance training) or innate genetic defects (i.e., DMD), muscle 
regeneration is characterized by two phases: a degenerative phase and a regenerative phase 
(Figure 1.2A).  
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 1.2 Skeletal muscle repair process 
The initial event of muscle degeneration is necrosis of the muscle fibers. Figure 1.2B 
 10 µm cross sections of mice gastrocnemius muscle stained with H&E. Injury by 
toxin (CTX) injection in the muscle results in a rapid necrosis of myofibers and the 
tion of an inflammatory response leading to the loss of muscle architecture (compare 
 1.2B with Figure 1.1B) including the formation of fibrosis (Figure 1.2B, arrow). This 
is generally triggered by disruption of the myofiber sarcolemma resulting in increased 
ber permeability and disruption of the myofiber integrity. The early phase of muscle injury 
3 
 is usually accompanied by the activation of mononucleated cells, principally inflammatory cells 
and myogenic cells. Present reports suggest that factors released by the injured muscle activate 
inflammatory cells residing within the muscle, which in turn provide the chemotactic signals to 
circulating inflammatory cells (reviewed in Refs. [3, 4]). Neutrophils are the first inflammatory 
cells to invade the injured muscle, with a significant increase in their number being observed as 
early as 1–6 hours after myotoxin or exercise-induced muscle damage [5, 6]. After neutrophil 
infiltration and ∼ 48 hours post-injury, macrophages become the predominant inflammatory cell 
type within the site of injury [4, 6]. Macrophages infiltrate the injured site to phagocytose cellular 
debris and may affect other aspects of muscle regeneration by activating myogenic cells [7-10]. 
Thus muscle fiber necrosis and increased number of nonmuscle mononucleate cells within the 
damaged site are the main histopathological characteristics of the early event following muscle 
injury (Figure 1.2C).  
Myofiber regeneration is characterized by the activation of myogenic cells to proliferate, 
differentiate, and fuse to necrotic fibers for repair or to each other for new fiber formation. 
Notably, the expansion of myogenic cells provides a sufficient source of new myonuclei for 
muscle repair (reviewed in Refs. [11-13]). Numerous nuclear radiolabeling experiments have 
demonstrated the contribution of dividing myogenic cells to regenerate myofibers, by 
proliferation phase to form new muscle fibers followed by myogenic cells differentiation and 
fusion into mature muscle fibers [14-16]. Long-standing histological characteristics are still used 
to identify the mammalian skeletal muscle regeneration process. On muscle cross-sections, 
regenerating fibers are characterized by their small caliber and their centrally located myonuclei 
(Figure 1.2D, white arrowhead). Once fusion of myogenic cells is complete, newly formed 
myofibers increase in size, and myonuclei move to the periphery of the muscle fiber (Figure 
4 
 1.2D, black arrow). Moreover, on muscle longitudinal sections and in isolated single muscle 
fibers, central myonuclei are observed in discrete portions of regenerating fibers or along the 
entire new fiber, suggesting that cell fusion is not diffuse during regeneration but rather focal to 
the site of injury [17]. In a time dependent manner after injury, the regenerated muscle fibers will 
become almost morphologically and functionally indistinguishable from undamaged muscle. 
 
 
 
 
1.3 DUCHENNE MUSCULAR DYSTROPHY: A SKELETAL MUSCLE DISORDER 
 
 
Duchenne muscular dystrophy (DMD) is a devastating muscle disease affecting about 1 in 3500 
boys in all populations. It is an X-linked recessive disorder [18] where a mutation in the 2.5 
million bp gene results in a failure to produce the 427 kDa protein called dystrophin at the 
sarcolemma of the muscle fibers [19-21]. Dystrophin and dystrophin associated protein complex 
(DAPC) form a link between the intracellular actin-based cytoskeleton and the extracellualr 
matrix (ECM) which plays a major role in maintaining plasma membrane integrity and stability 
[22-24] (Figure  1.3).  Disruption of this complex leads to increased susceptibility to contraction-
induced injury and sarcolemmal damage leading to myofiber necrosis [(Figure 1.4, compare 
normal human skeletal muscle (A) with dystrophic muscle (B)]. Indeed, upon muscle injury, a 
finely orchestrated set of cellular responses is activated, resulting in the regeneration of a well-
innervated, fully vascularized, and contractile muscle apparatus. This repair process is present in 
DMD, but is not efficient enough to compensate for the necrotic process and fibrosis. Thus, in 
DMD patients, repeated cycles of degeneration-regeneration would exhaust the regenerating 
potential of myogenic precursor cells leading to massive activation of connective tissue that 
5 
 results in muscle fibrosis [18] causing the muscle to undergo progressive weakness and wasting 
[25] which eventually leads to congestive cardiac and respiratory failure before adulthood. 
Despite extensive research in developing an effective approach of dystrophin delivery in 
dystrophic muscle (e.g., cell and gene therapy), there is no therapy capable of substantially 
slowing the course of the disorder and rescuing the diseased muscle tissue.  
 
 
 
 
Figure 1.3 Membrane stabilization by dystrophin protein interaction with intracellular 
cytoskeleton, actin filaments, and the extracellular matrix (Adapted from Expert Reviews in 
Molecular Medicine 2002, Cambridge University Press) 
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Figure 1.4 Immunohistochemical dystrophin labeling of skeletal muscle biopsies, taken from 
a normal individual versus a patient with Duchenne’s muscular dystrophy (Courtesy of  Johnny 
Huard, PhD, Pittsburgh, PA) 
 
 
1.3.1 Animal Model of DMD 
 
 
The biochemical and genetic animal homologue to human DMD is the mdx mouse. It is a 
spontaneously occurring mouse line deficient for dystrophin due to a point mutation in exon 23 
of the dystrophin gene, which forms a premature stop codon [26]. The mdx mouse with less that 
10% of the normal amount of dystrophin, and less than 0.1-0.01% of muscle fibers staining 
positively for dystrophin, is considered a true genetic homologue of DMD [27]. Although mdx 
mice are normal at birth, skeletal muscles show extensive signs of muscle degeneration by 3–5wk 
of age [28-30]. This acute muscle degeneration phase is accompanied by an effective 
regeneration process leading to a transient muscle hypertrophy [28, 29]. After this period, the 
degeneration/regeneration activity continues at lower and relatively constant levels throughout 
the life span of the animal. In fact, muscle of mdx mice differs from DMD patients in that it 
exhibits a greater degree of compensatory muscle regeneration and a scar fibrotic replacement 
7 
 [28]. However, for reasons that remain unclear, in the older animals (∼15 months), the muscle 
regeneration process is defective and the mice become extremely weak and die before wild-type 
littermates [31-33]. Such a milder histopathological modification is reflected by a slower 
progression of the disease. 
 
 
 
 
1.4 CURRENT TREATMENTS AND THEIR LIMITATIONS 
 
 
Two different therapeutic approaches have been explored in an effort to deliver normal 
dystrophin to murine and human dystrophic muscle: cell therapy based on myoblast 
transplantation (MT) and ex vivo gene therapy based on viral and non-viral vectors. 
MT involves transplantation of primary myoblasts into defected muscle which contribute 
to the formation of new muscle fibers during repair and regeneration, and help in delivery of 
dystrophin [34-42]. The initial animal experiments and clinical trials, however, have suggested 
that although myoblast transplantation is feasible and introduced donor cells have fused with 
host myofibers around the site of injection and produced normal dystrophin [43-45], the amount 
of muscle fiber expressing dystrophin  was not therapeutically significant and rather inefficient 
[39, 41, 42, 45, 46].  Donor cells may have also suffered from poor spread from the injection site, 
a low survival rate, and immune rejection by the host system [47-54]. In animal experiments, 
immunodeficient animals and/or immune-suppressive regimens [40, 44, 48, 55, 56], 
preirradiation of the injected muscle [44], and myonecrotic agents [35, 48] have been used 
extensively to improve the success of this technique. Although these approaches may be used to 
improve the restoration of dystrophin in mdx mice, the success of this technique remains rather 
8 
 limited and for the most part, clinically impractical. To minimize the problem of immune 
rejection in human, autologous myoblast transfer has been employed, where primary myoblasts 
are removed from a patient via biopsy, expanded in cell culture, genetically manipulated with 
therapeutic genes, and re-introduced to the same patient. This technique therefore permits the 
introduction of myoblasts capable of expressing the transgene into defected muscle. 
Virus-mediated delivery of the dystrophin gene to alleviate the biochemical deficiency in 
skeletal muscle became more of the research focus as a novel and attractive alternative. Viral and 
non-viral vectors have evolved rapidly. Plasmid, DNA, liposomes, viral vectors (e.g., 
adenovirus, adeno-associated virus, retrovirus, and herpes simplex virus) have already been used 
in the approach for gene delivery to muscles [57-64]. Two basic approaches for local gene 
therapy in the musculoskeletal system have been extensively investigated. Either the vectors are 
injected directly into the host tissue (in vivo) or the cells harvested via biopsy from different 
tissues (e.g., mesenchymal stem cells, muscle-derived cells, or dermal fibroblasts) are expanded 
in vitro,  genetically engineered (transduced/transfected) in vitro, and re-introduced to the same 
patient (autologous) where they either replace degenerated fibers (as in the case of DMD) or 
form additional fibers expressing the desired gene (ex vivo) [65-67]. 
The advantage of direct (non-cell-based) approaches are low toxicity and 
immunogenicity [68], but the inability of most viral vectors to efficiently transduce or infect non-
dividing muscle fibers is one of the major limitations [61, 69, 70].  In addition, the choice of the 
target cell is limited by the location of the defect, and insertion of genetic material into a specific 
type of cell is difficult to control. One way to overcome the difficulties of the direct 
approach and to help maximize the gene transfer efficiency and stabilize the expression was to 
develop an ex vivo method of gene transfer [71-80]. The ex vivo method has been 
9 
 successfully used to deliver dystrophin in dystrophic muscle of mdx mice [81]. In 
humans, this method was used in the clinical setting to deliver and express factor IX for 
hemophilia B [80], interleukin 1 receptor antagonist protein for arthritis [82], human 
pro-insulin for diabetes [83], tyrosine hydroxylase for Parkinson’s disease [84], and 
human growth factor for growth retardation [77]. The advantage of this method is 
multifaceted. First, the gene manipulation takes place outside the body (in vitro), 
thereby bypassing the need to inject massive amounts of virus into the patient. Also, we 
can select cells after transduction by special markers (e.g., neomycin) to increase the 
transduction efficiency and expression of the desired protein. In addition, this method 
give us enormous flexibility because we can choose the ideal cells for specific 
deficiency, For example, in case the of muscular dystrophies, muscle-derived stem cells 
would be an ideal choice for ex vivo gene therapy, with the reasons for this being 
discussed in detail in next the section. 
It is important to realize that ex vivo gene therapy is not without limitations. It is clear that 
immunological problems associated with virally transduced cells still limit this technique. The 
efficiency of retroviral vector-mediated gene transfer is highly variable depending upon the 
vector design, the titer of the package virus, the type and species of the target cell, and is strictly 
dependent upon cell replication [85].  The integration of viral vectors into the genome of cells 
bears the risk of mutagenesis and the development of a potential malignancy. Consequently, all 
gene therapy techniques should be regarded with extreme caution. However, with viral vectors 
continuously being engineered to be less immunogenic, major advances can be expected in the 
near future. 
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1.5 MUSCLE-DERIVED STEM CELLS: POTENTIAL FOR MUSCLE 
REGENERATION 
 
 
Stem cells are undifferentiated cells with unique features including i) appearance in early 
development and persistence throughout life; ii) self-renewal ability resulting in a large number 
of progeny; iii) long term proliferation potential while maintaining transient quiescent state; and 
iv) multilineage potential to enhance the new cell’s incorporation into injured or diseased tissues. 
The stem cells’ definition primarily emerged through extensive research on marker profiles, self-
renewal, and the multi-potential behavior of hematopoietic stem cells (HSCs). On that note, the 
different populations of muscle-derived progenitor cells also appear to exhibit varied degrees of 
pluripotency. The most well-characterized muscle progenitor cells are satellite cells [86], usually 
referred to as “muscle stem cells.” These unique undifferentiated myogenic cells have a 
committed fate and can regenerate injured skeletal muscle very efficiently [87, 88]. In addition to 
participating in the formation of myofibers, satellite cells can also differentiate into other 
lineages, such as adipocytic, osteoblastic, and chondrogenic [89, 90]. Satellite cells are integral 
to the development of skeletal muscle during embryogenesis and the regeneration of muscle 
fibers during postnatal life. During postnatal life, these cells are mitotically quiescent and reside 
between the basal lamina and the sarcolemma of myofibers. During the need for perceived 
growth or during post-natal reparative responses to stress or damage, satellite cells become 
activated, migrate, re-enter the cell cycle, differentiate, and fuse to form new regenerating 
myofibers [87, 88, 91]. Researchers have investigated the injection of satellite cells/myoblasts as 
a means to promote muscle repair in both animals and humans [88, 89]. The results suggest that, 
although the injected cells can improve muscle regeneration, various limitations such as poor 
11 
 survival, limited dissemination of the injected cells, and immune rejection limit the success of 
this technique [47-54]. The development of using stem cells for transplantation may enable 
scientists to overcome these limitations because stem cells in theory are capable of long term 
proliferation, efficient self-renewal, and multilineage differentiation, all of which can improve 
the long-term survival of the cells post-transplantation [37, 92-94]. Investigators in our lab have 
obtained early myogenic progenitor cells highly proliferative, late-adhering, and Sca-1[+]/CD34 
[+]/CD45[–]/c-Kit[–] called muscle-derived stem cells (MDSCs) using a preplating enrichment 
technique [95] (for details refer to Appendix A). This technique separates myogenic cells based 
on their adhesion to collagen-coated flasks. The fraction of more committed myogenic cells that 
were attached to bottom of flask at early time points [early preplate (EP)] exhibit in vitro marker 
profiles, as well as proliferation and fusion behavior comparable to that of  satellite cells (Table 
1.1). The cell population from the late preplate (LP) were called long-term proliferation (LTP) or 
muscle-derived stem cells (MDSCs). 
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Table 1.1 The Marker profile comparison between myogenic, stem, and blood cells, adapted 
from [96, 97] 
 
 
Cell Types Cell Markers * EP LTP (MDSCs) 
Desmin + -/+ 
M-cad + - 
Myogenic cells 
 
 Pax7 + - 
CD34 -/+ +(+) 
Sca-1 -(N) +(+) 
   
Bcl-2 -(N) +(+) 
Stem cells 
Flk-1 N +(N) 
c-Kit - - Blood Cells 
 CD45 - - 
 
 
 
+: >90%, -: <5%, -/+: 5-30%, +/-: 40-80%, N: Not determined 
*(refer to nomenclature for marker profiles name and description) 
 
MDSCs have unique characteristics usually associated with non-committed progenitor cells such 
as i) long term proliferation ability in vitro and in vivo, ii) high self-renewal, iii) multipotent 
differentiation capability (particularly into blood vessel and nerve); and iv) immune-privileged 
behavior [96, 98].  In addition, MDSC are c-Kit[–]/CD45[–], eliminating their potential 
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 hematopoietic origin. Moreover, they spontaneously express myogenic markers, MyoD and 
desmin (Table 1).  Finally, the MDSCs have a high potential for myogenic differentiation in vitro 
and in vivo, when compared with satellite cells, and they display a significant improved 
transplantation capacity (higher number of dystrophin (+) myofibers) starting at 10 days up to 30 
and 90 days post-transplantation in gastrocnemius of mdx mice [96].  
Until recently, the satellite cells were presumed to be the sole source of myonuclei in muscle 
repair. However, recent findings have demonstrated the presence of multi-potential stem cells in 
various adult tissues, thereby challenging the widely held view that tissue-specific stem cells are 
predetermined to a specific tissue lineage. In fact, adult stem cells isolated from various tissues 
appear to differentiate in vitro and in vivo into multiple lineages depending on environmental 
cues. Progenitor cells isolated from bone marrow (BM) [37, 99-101], the adult musculature [37, 
96, 102-104], the neuronal compartment [105, 106], and various mesenchymal tissues [107, 108] 
can differentiate into the myogenic lineage. In particular, BM and muscle adult stem cells have 
been shown to differentiate into muscle cells in vitro and to contribute to muscle regeneration in 
vivo (for review, see Refs. [12, 109, 110]). Although these various types of cells appear to be 
able to differentiate toward myogenic lineage their regeneration capacity in skeletal muscle is 
limited. Therefore, MDSCs compared to many other cell types are better candidates for skeletal 
muscle transplantations, particularly because these cells can highly regenerate skeletal muscle, 
be obtained easily from a superficial muscle biopsy (non-invasive manner) from patients, be 
expanded to the desire number, and most importantly, through multi-potential differentiation into 
endothelial and neural lineages, they may enhance the neural and vascular supply during muscle 
regeneration [96].  
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1.6 ROLE OF GROWTH FACTORS IN MUSCLE REGENERATION 
 
 
General terms such as hormone, cytokine, and growth factor are principally of historical interest.  
Specific terms such as nerve growth factor were derived form early descriptions of a factor’s 
action or source, consequently, such terms do not necessarily provide meaningful descriptions of 
their function but rather they exist as identifiers accepted by tradition. There are small proteins 
that serve as signaling agents for cells. Despite being present in plasma or tissue at 
concentrations that are generally measured in picomolar (ng/ml) range, growth factors are the 
principal effectors of such critical functions as cell division, matrix synthesis, and tissue 
differentiation in virtually every organ system [111].  
Figure 1.5 shows a schematic of the mechanism by which growth factors regulate cell 
behavior in general. Growth factors elicit their cellular actions by binding to specific 
transmembrane receptor molecules (Receptor-binding domain) on their target cells membrane. 
These receptors serve as information transducers, converting information carried by a growth 
factor into a form that is usable by the cell. This ligand-receptor interaction activates the 
intracellular domain of the receptor (kinase domain) which possesses the enzymatic ability to 
transfer phosphate groups to proteins (kinase activity). This acts as an intracellular 
communication step.  The presence or absence of the receptor defines whether or not a cell can 
respond to information in its external environment. Growth factor receptors are linked by a 
cascade of chemical reactions in the cytoplasm to various genes in the nucleus with the binding 
of transcription factors (proteins that bind to specific regulatory sequences of DNA) to activate 
gene transcription into messenger RNA (mRNA). The mRNA is then transcribed into protein to 
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 be used within the cell. Often this cascade activates several genes at once. As a result, when use 
of a growth factor is considered to treat a specific cell defect, one must be aware that the factor 
may generate multiple effectors, even within a single cell type. While these results may be 
advantageous (as when both cell division matrix synthesis are desired for a repair response), it is 
a theoretical disadvantage if so-called mismatched effects (for example, cell division and matrix 
degradation) are stimulated simultaneously. Each family of growth factors has its own 
corresponding family of receptors. Despite marked differences in structure among receptor 
families, many of the key links in the gene-activating chain of reactions are shared by these 
families. Thus, binding of different growth factors to their respective receptors may lead to the 
same cellular response (such as cell division). Much more impressive than the similarities among 
post-receptor pathways, and much less well understood, are the differences. Many growth factors 
display pleiotrophic activity, eliciting a variety of effects in different stages of development. 
Although it is not yet clear how this remarkable versatility is achieved, these specific 
mechanisms probably will be important in the design of growth factor therapies that will be 
capable of activating only certain genes and not others. Knowledge about receptors is crucial to 
the successful application of growth factors as therapeutic agents. Clearly, treatment with growth 
factors will not help a problem caused by abnormalities in the receptor for that factor. In 
addition, the growth factors must be regulated, so as not extend treatment beyond the therapeutic 
level and to prevent overgrowth of various tissues in the target area. 
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Figure 1.5  
adapted from
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 [111] 
well documented that growth factors can regulate skeletal myoblast proliferation and 
on in vitro [112, 113] and act as stimulators or inhibitors (Table 1.2). Various growth 
thought to play a role in different stages of muscle generation [114, 115] by 
satellite cells to release, proliferate, and terminally differentiate [116-119]. These 
regulate muscle regeneration in vivo must act to maintain a balance between growth 
tiation in order for restoration of normal tissue architecture to occur. It is likely that a 
 of many growth factors is involved in the regulation of myogenesis during muscle 
t and regeneration. The insulin-line growth factor (IGFs), basic fibroblast growth 
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 factor (bFGF), platelet-derived growth factor (PDGF), leukemia inhibitory factor (LIF), and 
transforming growth factor beta (TGF-β) have been localized to muscle cells or other cell types 
present in muscle tissue [113, 120-123]. Expression of bFGF and the IGFs have been examined 
in regenerating skeletal muscles by immunocytochemistry and in situ hybridization, and they has 
been found to be up-regulated compared to non-injured muscles [121, 124, 125]. The pre-
treatment of myogenic cells in culture with bFGF has shown to promote cell proliferation, 
resulting in an up to four-fold increase in myofiber regeneration [126]. In the mouse model, the 
IGF-1, bFGF, and to a lesser extent, nerve growth factor (NGF), directly injected post-injury 
have enhanced muscle regeneration in lacerated, contused, and strain-injured muscle [127-138]. 
 
 
 
Table 1.2 Effect of growth factors on the proliferation and fusion of myoblasts in  vitro, 
adapted from [130]  
 
 
Growth Factor* Proliferation Fusion 
bFGF Stimulates Stimulates
IGF-1 Stimulates Stimulates
NGF Stimulates Stimulates
α-FGF Inhibits Inhibits 
PDGF Inhibits Inhibits 
EGF Inhibits Inhibits 
TGF-α Inhibits Inhibits 
TGF-β Inhibits Inhibits 
 
*(refer to nomenclature for the list of growth factors name) 
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 While, in the past few years, much has been learned about the effects of these factors on 
musculoskeletal tissues, and a few notable therapeutic successes have been achieved, the 
understanding of their role in muscle diseases remains rudimentary. With continued progress in 
the basic science and clinical investigation of these factors, it is probable that they will become 
the method of choice for the prevention and treatment of a variety of current unsolved problems. 
 
 
1.6.1 Nerve Growth Factor― NGF 
 
 
The term “NGF” was introduced 50 years ago as a target-derived neutrophic factor that is 
essential for the development, survival, and differentiation of developing neurons in the 
peripheral sympathetic and sensory neurons [139, 140]. NGF belongs to the neurotrophin family 
of growth factors that are synthesized as precursors (pro-neurotrophins) that are proteolytically 
cleaved to mature and biologically active form [141]. Because neurotrophins are normally 
expressed at low levels, little is known about their processing and secretion by neurons and non-
neuronal cells in vivo.  
The ideas about the biological role of NGF have been dominated by concepts that arose 
from studies on the differentiation and survival of young neurons. Until recently, the expectation 
was that the biology of NGF would center on the classical target-derived neurotrophic factor 
paradigm in which NGF released by postsynaptic targets acts on presynaptic neurons to build or 
maintain functional contacts and enhance the function of well-defined neural circuits. Although 
this paradigm undoubtedly plays a critical role in both the peripheral nervous system (PNS) and 
central nervous system (CNS), it does not appear to be the sole role for NGF actions suggesting 
this molecule may have broader physiological effects. For example, NGF has been reported to be 
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 expressed by the luminal epithelium of the epididymis and the germ cells of the rat and mouse 
testes [142],  and the circulation levels of NGF change not only with age, but also during 
neuroendocrine disregulation, after neurological insults, and during autoimmune and allergic 
diseases [143-149]. More relevant to the work being presented here, NGF has been shown to 
promote the differentiation of muscle cells in culture [150]. Furthermore, Rende at al. in 2000 
showed that NGF expression in skeletal muscle is not only associated with a classical target-
derived neurotrophic function for peripheral nervous system neurons, but also with an autocrine 
action (locally binding to cell-surface receptors on the same cells that produced it) which affects 
the proliferation, fusion into myotubes, and cell morphology of developing myoblasts, thereby 
suggesting that among other roles, endogenous NGF signaling through both neurons and non-
neuronal cells subserves neuroprotective functions and facilitates muscle repair. The regulated 
expression of NGF throughout adult life suggests multiple functions for NGF signaling, many of 
which are poorly understood. 
 
 
1.6.2 NGF Receptors: TrkA and p75NTR 
 
 
The NGF functions as a dimmer of identical subunits linked together by noncovalent 
bonds and with molecular mass of about 26 kDa [151]. The functional activity of NGF is 
mediated by two classes of receptors: high-affinity receptor, TrkA (kd =10-11 M), and low-
affinity receptor, p75NTR (Kd=10-9 M)  [152-156]. 
A schematic drawing of the structural features of Trk and p75NTR is displayed in Figure 
1.6. TrkA is a 140 kDs single-pass transmembrane protein with a single transmembrane domain 
and a single cytoplasmic tyrosine kinase domain that serves as a receptor tyrosin kinase (RTK) 
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 for NGF. Neurotrophin-mediated activation of TrkA receptor leads to a variety of biological 
responses and elicits many of the classical neurotrophic actions ascribed to NGF, including 
proliferation and survival, axonal growth and remodeling, assembly and remodeling of 
cytoskeleton [157-159].  p75NTR is a 75-kDs transmembrane glycoprotein that belongs to a 
superfamily of cytokine receptors which includes TNF receptors (TNFR), Fas, CD27, CD40, and 
CD30. p75NTR binds all members of the neurotrophin family with approximately equal 
nanomolar affinity, and is therefore referred to as a neurotrophin receptor, and not as an NGF 
receptor. p75NTR has a distinctive extracellular-domain sequence that differs with TrkA, with 
four distinct cytosine-rich domains that are responsible for ligand-binding. The precise role of 
p75NTR in NGF signal transduction has not been fully elucidated. Several studies have indicated 
that stimulated of TrkA is necessary and sufficient to elicit a full biologic response and is 
required for cell survival, while other reports have highlighted the crucial role of the association 
of TrkA and p75NTR in regulating NGF biological activities on NGF-responsive cells [155]. 
These studies shed light on the often conflicting roles for p75NTR in mediating apoptosis and in 
augmentation Trk-induced survival and differentiation. The selectivity of proNGF for p75NTR 
suggests that its local secretion may determine whether apoptotic or survival actions 
predominate.  
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Figure 1.6 A schematic drawing of the structural features of Trk and p75 receptor, adapted 
from www.izn.uni-heidelberg.edu.de/download/LFB2004/Tucker.pdf
 
 
 
 
1.7 MDSCs & NGF AS A REMEDY FOR TISSUE ENGINEERING 
 
 
Tissue Engineering has been defined as the application of the principles and methods of 
engineering and life sciences towards the development of biological substitutes to restore, 
maintain, or improve functions. It is our expectation that a cell-based therapy can help to provide 
a solution to the growing problem of tissue and organ failure. Therefore, there has been growing 
enthusiasm for a tissue-engineering approach that aims at utilizing stem cells to deliver genes of 
interest to improve healing of the musculoskeletal system. The feasibility of direct injection of 
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 human recombinant growth factors for treatment of muscle injuries due to its safety and ease is 
practically hindered because high concentrations of the growth factor are often required to 
produce the beneficial effect. Indeed, studies have shown that growth factors exhibit a dose-
dependent effect on myoblasts proliferation and differentiation in vitro, while in vivo, three 
consecutive injections of high concentration (100 ng) NGF, IGF-1, and bFGF are required to 
improve muscle healing in the mice model [127-138]. The relatively short biological half-life, 
the bloodstream’s rapid clearance, and the limited adequate duration of growth factor delivery 
are the main reasons why large concentrations of growth factors are typically required.  
In this regard, isolated muscle-derived stem cells obtained through the preplate technique 
would be the perfect candidate for cell-mediated therapy and the perfect choice for ex vivo gene 
delivery since these cells show i) long-term proliferation and self-renewal capacity ii) 
multilineage differentiation ability (e.g., myogenic, neurogenic, osteogenic, adipogenic, 
hematopoietic, and chondrogenic), and iii) potential immune-privileged behavior (i.e., the failure 
to trigger the immune response). While the direct in vivo injection of growth factors or stem cells 
is technically less complex, the indirect, ex vivo, gene delivery technique is safer because the 
gene manipulation (i.e. genetically engineering using viral vectors) takes place under controlled 
conditions outside the body. With the ex vivo approach, growth factors can be delivered using 
endogenous cells. These cells are capable of responding to stimuli created by injured tissue and 
can participate in healing process more effectively by delaying, ameliorating, or arresting the 
further degeneration. 
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2.0 PROJECT OBJECTIVES 
 
 
 
 
The overall goal of this project is to evaluate a novel tissue engineering method for skeletal 
muscle repair. Both muscle-derived stem cell transplantation and ex vivo gene therapy are 
excellent candidates for growth factor delivery. We propose that direct stimulation of MDSCs 
with nerve growth factor (NGF) protein and genetically engineering MDSCs with retroviral 
transduction used for sustained delivery of NGF can hold great promise as the basis for tissue 
engineering and gene therapy applications to acquire muscle healing. The development of such a 
novel therapeutic strategy hold tremendous potential for the treatment of pathological conditions 
associated with poor muscle regenerative capacity, such as those observed during injuries and 
muscular dystrophies.  
 
 
 
 
2.1 OBJECTIVE 1: EXAMINE THE PHENOTYPIC EFFECT OF NGF 
STIMULATION ON MDSCS IN VITRO. 
 
 
A variety of growth factors epidermal growth factor (EGF), fibroblast growth factor-2 (FGF-2), 
insulin-like growth factor-1 (IGF-1), and stem cell factor (SCF) have been shown to be potent 
stimulators of the proliferation and myogenic differentiation of MDSCs in vitro [160]. The 
current study aims to address the phenotypic behavior (proliferation and fusion) of MDSCs 
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 under the influence of NGF. Two stem cell markers: Sca-1 and CD34 and two myogenic 
markers: desmin and Pax7 will be examined before and after NGF stimulation. The proliferation 
kinetics and myogenic cell behavior of the control and stimulated MDSCs will be monitored 
using a novel bioinformatic cell culture imaging system, allowing time-lapse image analysis, 
including cell division time and fusion behavior. The myogenic differentiation capacity of these 
cells will be investigated by the ability of cells to differentiate in vitro and to fuse and form 
myotubes. We hypothesize that MDSCs’ marker profiles will remain the same while the 
myogenic marker expression, proliferation kinetics, and myogenic differentiation will change 
following NGF stimulation. 
 
 
 
 
2.2 OBJECTIVE 2: EVALUATE THE EFFECT OF NGF STIMULATION ON 
MDSCS’ REGENERATION  CAPACITY. 
 
 
Our preliminary studies indicate that growth factors promote the multipotent differentiation of 
MDSCs into muscle fibers, blood vessels, and peripheral nerve. They may also contribute to the 
formation of functional skeletal muscle tissue with adequate vascular and neural supplies. We 
hypothesize that NGF stimulation will promote multilineage differentiation, which in turn 
enhances engraftment efficiency (higher number of dystrophin-positive myofibers) and improves 
the regeneration capacity of MDSCs in mdx skeletal muscle. 
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3.0 INTRODUCTION 
 
 
 
 
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder characterized by 
dystrophin deficiency that results in initial necrosis of muscle fibers, which in turn leads to 
progressive muscle weakness and, ultimately, death before or shortly after patients reach the 
second decade of life [19, 161]. Dystrophic muscle has a heightened susceptibility to structural 
damage and a decreased capacity to undergo self-repair. 
Researchers have localized dystrophin in the sarcolemma of myofiber [162-164], where it 
is thought to play a role in maintaining plasma membrane integrity and stability [22-24]. Like the 
muscles of humans with DMD, the muscles of mdx mice are dystrophin deficient [165], which 
makes the mdx mouse an excellent genetic and biochemical model for DMD. Unlike the muscles 
of humans with DMD, however, the muscles of mdx mice show no progressive weakness or 
progressive fibrosis; instead, they exhibit muscle hypertrophy and maintain their regeneration 
capacity [166].  
Although lack of dystrophin leads to progressive muscle degeneration, the evolution of 
DMD is likely to be dependent upon other factors, such as insufficient expression of growth-
associated proteins. After skeletal muscle damage, quiescent myogenic stem cells, which are 
normally embedded in the basal lamina of the muscle fibers, are activated and migrate toward the 
damaged area, where they undergo a cycle of proliferation, fusion, and differentiation that 
culminates in the generation of myofibers that replace the damaged ones [167]. In most cases, 
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 myogenic differentiation is measured as increased expression of muscle cells functions such as 
creatine kinase activity, fusion of single cells to form myotubes, or elevation of myosin heavy or 
light chain expression, or other proteins associated with the contractile apparatus. Various 
growth factors can regulate skeletal myoblast proliferation and differentiation and are known to 
play a role in different stages of new muscle regeneration, therefore enhancing the healing 
process [111, 114, 115]. In addition to stimulating cell proliferation, growth factors can maintain 
cell survival and regulate critical intracellular signal transduction pathways [168] under 
conditions that otherwise lead to apoptotic death. 
To date, the list of growth factors known to affect the behavior of skeletal muscle cells or 
to be expressed in skeletal muscle tissue is extensive. However, few studies have investigated the 
role of NGF during skeletal muscle regeneration, and its exact mechanism of activity is poorly 
understood. In addition to acting as a target-derived factor for developing neurons, NGF has an 
autocrine effect on myoblast proliferation and fusion [169-171]. Moreover, adult knockout mice 
expressing a neutralizing antibody against NGF display a severe dystrophy and reduced muscle 
mass [172, 173]. Recent evidence suggests that NGF acts by binding to the high-affinity 
tyrosine-kinase receptor (TrkA) and the low-affinity p75-neurotrophin receptor (p75NTR). TrkA 
is found in developing adult rat myoblasts [174] and during differentiation of muscle cells [170]. 
NGF and p75NTR are widely expressed in myoblasts, human myocyte cultures, and regenerating 
myofibers in the muscle of DMD patients [175, 176].  
Previous studies in our laboratory have revealed that the delivery of human recombinant 
NGF protein via direct intramuscular injection improves both muscle recovery [130] and muscle 
force (fast-twitch strength) after strain injury [129]. However, the efficiency of direct 
intramuscular injection of growth factors varies according to the type of injury encountered and 
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 is limited by the need to maintain high enough concentrations to achieve a therapeutic effect. In 
addition, the use of growth factor proteins to promote healing is severely hindered by the 
difficulty of ensuring their delivery to the injured site [177], their short biological half-lives [66, 
177], and the bloodstream’s rapid clearance of these molecules. For the study reported here, we 
used a combination of MDSC-based gene therapy and direct stimulation with NGF protein to 
examine the effects of NGF on the proliferation and differentiation capacity of MDSCs in vitro 
and their regeneration efficiency in mdx muscle in vivo. 
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4.0 MATERIALS AND METHODS 
 
 
 
 
4.1 ANIMALS 
 
 
Mdx mice (C57BL/10SCsn DMDmdx/J) were purchased from the Jackson Laboratory (Bar 
Harbor, ME). All animal protocols used for these experiments were approved by the Children’s 
Hospital of Pittsburgh’s IACUC committee (protocol # 3/02). 
 
 
 
 
4.2 CELL ISOLATION AND CULTURING 
 
 
A previously described modified preplate technique [96] was used to obtain MDSCs from 
normal (C57BL/6J) 3-week-old female mice. Cells were cultured at an initial density of 450 
cells/cm2 in flasks coated with collagen type I (Sigma-Aldrich Corp., St. Louis, MO) and 
maintained in proliferation medium (Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% horse serum, 10% fetal bovine serum (FBS), and 1% penicillin-
streptomycin; all reagents from Gibco, Inc., Carlsbad, CA) containing 0.5% chick embryo 
extract (Accurate Chemical, Westbury, NY). After 2 days of growth (confluency < 50%), the 
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 cells were trypsinized, counted, and replated to generate the quantity of cells needed for each 
experiment. The preplating technique was used to purify slowly adhering MDSCs if necessary. 
 
 
 
 
4.3 GENERATION OF RETROVIRAL VECTOR EXPRESSING NGF 
 
 
NGF cDNA was amplified from plasmid pSP72NGFpA (provided by Dr. Paul Robbins) using 
primers NGF1 (agg cgg ccg ccc acc atg ctg tgc ctc aag cca gtg aaa) and NGF2 (tca aga tct tca gcc 
tct tct tgt agc ctt cct) and Pfu DNA polymerase (Stratagene, CA). The PCR product was cut with 
restriction enzymes Not I and Bg III and cloned into the same 2 sites of retroviral vector pCLX 
[178]. The vector DNA was converted into a replication-defective retrovirus by co-transfection 
(with calcium-phosphate precipitation) into packaging cell line GP-293 (Clontech, Palo Alto, 
CA) with a plasmid, pVSVG, which expressed vascular stomatitis virus glycoprotein as the viral 
envelope.  Conditioned medium containing retroviral vector was stored at -80 oC until use. 
 
 
 
 
4.4 STIMULATION OR RETROVIRAL TRANSDUCTION OF MDSCS WITH NGF  
 
 
MDSCs were plated at 20%–30% initial confluency and either stimulated with 100 ng/ml of 
NGF (Sigma-Aldrich) for 7 days (S-MDSCs) or retrovirally transduced with the CLNGF vector 
to express NGF (E-MDSCs) at a multiplicity of infection of 5 in the presence of polybrene (8 
µg/ml). Normal MDSCs neither stimulated nor transduced served as the control group (C-
MDSCs). E-, S-, and C-MDSCs were expanded for one week in proliferation medium (20% 
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 serum) at an initial density of 8x104cells/well on collagen type I–coated 6-well plates, where 
they remained for 48 hours;  proliferation medium was then replaced with low-serum medium 
(2% FBS) in which cells were cultured for an additional 24 hours. Tissue culture supernatant was 
collected and spun at 1200 rpm for 5 minutes at 4 °C, and the level of functional NGF secreted 
by the cells in the tissue culture supernatant was measured by enzyme-linked immunosorbant 
assay (ELISA) (NGF Emax® Immunoassay System kit, Promega, WI) performed as detailed in 
the manufacturer’s instructions.  
 
 
 
 
4.5 CELL CHARACTERIZATION BY FLOW CYTOMETRY 
 
 
Flow cytometry was used to analyze the expression of the cell surface markers cluster 
differentiation (CD34) and stem cell antigen-1 (Sca-1). Cultured cells were trypsinized, spun, 
washed in a buffer made of phosphate buffered saline (PBS) (Dulbecco phosphate-buffer salt 
solution 1X; Mediatech, Inc., Herndon, VA) containing 0.5% bovine serum albumin (BSA) (ICN 
Biomedicals) and 0.1% sodium azide (Sigma-Aldrich), and then counted. After trypsinization, 
the cells were maintained on ice for the remainder of the procedure. The cells were then divided 
into equal aliquots and spun into a pellet. A 1:10 mouse serum (Sigma-Aldrich) was used to 
resuspend each pellet, and the suspensions were incubated for 10 minutes on ice. Predetermined, 
optimal amounts of both direct and biotin-conjugated rat anti-mouse monoclonal antibodies 
(CD34 and Sca-1) were placed in each tube for 30 minutes. Each experimental tube received 
FITC-conjugate for CD34 and biotin-conjugated Sca-1. A separate cell portion received 
equivalent amounts of isotype control antibodies. After several rinses, all fractions (including the 
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 controls) were labeled with streptavidin-allophycocyanine (APC) for 20 minutes. Just before the 
analysis, 7-amino-actinomycin D (7-AAD) was added to each tube to exclude non-viable cells 
from the analysis. All antibodies, including APC and 7-AAD, were purchased from BD 
PharMingen (San Diego, CA). At least 10,000 live cell events were analyzed via flow cytometry 
(FACS Aria cytometer using FACS Diva software, Becton Dickinson, San Diego, CA). 
 
 
 
 
4.6 MYOGENIC MARKER EXPRESSION BY IMMUNOCYTOCHEMISTRY 
 
 
A fraction of each group was evaluated by immunofluorescent staining for expression of the 
myogenic proteins desmin and Pax-7. Analysis was performed on methanol-fixed cells that were 
blocked with 5% goat serum in PBS for 1 hour. The cells were incubated for 1 hour with the 
following primary antibodies: mouse IgG anti-desmin (1:250; Sigma-Aldrich) and mouse anti-
Pax-7 (1:50; R&D Systems, Minneapolis, MN). After being rinsed thoroughly with PBS, the 
cells were incubated for 30 minutes with the secondary antibody biotinylated goat anti-mouse 
IgG (1:250; Vector, Burlingame, CA). To fluorescently label the antigenic binding, the cells 
were washed and incubated with Streptavidin-Cy3 (1:500; Sigma-Aldrich) for 10 minutes; nuclei 
were then counterstained with DAPI (1:100; Sigma-Aldrich) in PBS. All dilutions were in 5% 
goat serum in PBS at room temperature. Negative control staining was performed using an 
identical procedure, with omission of the primary antibody. Northern Eclipse software (v.6.0, 
Empix Imaging, Mississauga, ON, Canada) was used to quantify the percentage of myogenic 
cells as the ratio of cells that strongly expressed desmin or Pax-7 to the total number of nuclei in 
10 randomly chosen fields at 200x magnification.  
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4.7 CELL DIVISION ANALYSIS   
 
 
The time lapse between cytokinesis events were recorded as the length of the cell division cycle 
from the time-lapsed video images from a novel microscope imaging system described below. 
For each population, 100 cells were selected and tracked. The division time (DT) of each cell 
was determined by direct observation of the cells from the time-lapsed video record. The 
initiation of cell division was marked at the time when two daughter cells were formed, and these 
cells were followed until their respective division. The lapse time between those two division 
events was recorded as the length of the cell division cycle. The average population doubling 
time (PDT) was calculated by fitting an exponential trend line to several measured data points. 
PDT was estimated by using the software package SigmaStat 2.0 (Jandel Scientific, San Rafael, 
CA) to perform nonlinear regression in order to generate the best fit to the curve. The fraction of 
daughter cells that were actively entering the mitotic cell cycle (α) was calculated from 
experimental data using PDT and DT and solving the re-arranged Sherley model to obtain the 
correlation coefficient (R2) for the nonlinear regression [179, 180], a value that indicates how 
well the data actually fit the model (such that 0 < R2 < 1.0).  
 
 
4.7.1 Experimental Settings 
 
 
Various cell culture and imaging settings such as cell plating densities, image acquisition 
intervals, duration of cell growth, viewfield limits, and optimized phase contrast have already 
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 been tested [181]. These settings are important in determining the best densities at which the 
cells are able to interact with each other, while remaining visible. This way, the events can be 
captured accurately without the cells being lost to follow-up. 
MDSCs from each group were plated at an initial density of 450-500 cells/well in a collagen 
type I–coated 12-well plate in 20% serum medium, as described in section 4.2. Cells were 
allowed to adhere for 6-12 hours. Using the microscopic imaging system, time-lapsed visible 
imaging was obtained for individual cells and subsequently, for growing colonies [182]. In these 
experiments, groups of 4 to 6 cells were selected for imaging. Coordinate positions of these view 
fields were recorded by the CytoWorks software program that subsequently controls the time and 
position of stage movement. Images of each view field were acquired at 10-minute intervals for 4 
days. For each cell type and treatment condition, 15 view fields were selected from 6 wells. Cell 
population growth was monitored by counting the total number of cells, N, in the view field at 
12-hour intervals.  
 
 
4.7.2 Imaging System 
 
 
Our imaging system showing in Figure 4.1 consists of a customized mechanical stage containing 
a cell culture system and microscopy (Nikon Eclipse TE-2000-U microscope) specifically 
designed for time-lapsed imaging over long periods of time. In the system, an environmentally-
controlled biobox incubator is mounted to the stage of the microscope, which is in turn linked to 
a CCD camera (Automated Cell Technologies, Inc., Pittsburgh, PA). The x-y position of the 
stage is under the control of the user such that any position on a culture plate can be selected for 
viewing. The system accommodates any sized multi-well plates from 6-well to 384-well. 
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 Multiple viewfields can be selected in each well. Each view field or x-y position that is selected 
becomes the location for time-lapsed imaging. Individual images are directly recorded in jpeg 
from the continuous images. Automated measures of the total numbers of cells can made at any 
time point and the division times can accurately determined by direct observation of cytokinesis. 
 
 
 
 
 
 
Figure 4.1 Bioinformatic Cell Culture and Imaging System (Courtesy of Bridget Deasy, 
PhD, Pittsburgh, PA)  
 
 
4.7.3 Non-exponential Growth Model 
 
 
This model was proposed by Sherley [180] and is particularly well-suited for studying the 
expansion of all cell populations and estimation of division time, mitotic fraction or population 
doubling time. Consequently, this model enables researchers to assess the behavior of a 
particular cell population under various culture conditions. The model is based on the Sherley 
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 equation that is easy to use and offers a simple way of modeling cell growth for stem cell 
biologists based on the fraction of daughter cells that are dividing, α, while accounting for the 
presence of non-dividing cells: 
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where N is the number of cells at any time t, N0 is the initial number of cells, and both DT and 
cell number at each time point are determined by image analysis directly through individual 
observations of cytokinesis. A brief derivation of this model, including assumptions inherent to 
its use, is provided in Appendix B. 
 
 
 
 
4.8 MYOGENIC DIFFERENTIATION 
 
 
Myogenic differentiation was evaluated by immunocytochemical staining for fast myosin heavy 
chain (MHC) expression. E-, S-, and C-MDSCs were plated at an initial density of 1000 
cells/cm2 in multi-well collagen type I–coated 12-well plates in high-serum DMEM (details 
above) for 2 days. To induce fusion, proliferation medium was replaced with differentiation 
medium (low serum: DMEM supplemented with 2% FBS and 1% penicillin-streptomycin) for an 
additional 3 to 4 days. Immunocytochemistry staining was performed as described above with 
the monoclonal mouse anti-MHC (1:250; Sigma-Aldrich) as the primary antibody to reveal fast 
MHC expression. Nuclei were visualized by DAPI (1:100; Sigma-Aldrich). Representative fields 
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 were evaluated to determine the degree of differentiation (percent ratio of MHC-expressing 
nuclei to total number of nuclei), an indicator of differentiation efficiency. 
 
 
 
 
4.9 MYOFIBER REGENERATION IN VIVO 
 
 
A total of 2–3x105 C-, E-, or S-MDSCs were injected into the gastrocnemius muscle of 6–8 
week-old male mdx mice. Mice in the E-MDSC group and their controls were 
immunosuppressed by subcutaneous injection of FK506 (2.5 mg/kg mouse body weight/day) 
beginning on the day of cell transplantation and continuing until the day of sacrifice [183]. Ten 
to fourteen days after transplantation, the gastrocnemius muscles were harvested, flash frozen in 
liquid nitrogen–cooled 2-methylbutane, and serially sectioned (10 µm). Dystrophin staining of 
cryopreserved tissue was performed on acetone-fixed, horse serum–blocked sections using a 
rabbit anti-dystrophin antibody (1:1000; provided by Dr. Terry Partridge) for 3 hours. Sections 
were then washed in PBS and incubated with biotinylated anti-rabbit IgG antibody for 1 hour. 
Next the sections were washed again and incubated with Streptavidin-Cy3 (1:300; Sigma-
Aldrich) for 20 minutes. All incubations were at room temperature. Fluorescence microscopy 
was performed and digital images were acquired. Muscle regeneration was assessed by counting 
the number of dystrophin-positive myofibers in an area containing the largest graft and 
calculating the regeneration efficiency index (RI: the number of dystrophin-positive fibers in the 
host muscle per 105 donor cells) for ease of comparison and graphical display [103].  
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 4.10 QUANTIFICATION OF DYSTROPHIN-POSITIVE MYOFIBERS USING 
NORTHERN ECLIPSE 
 
 
The digital images of regenerated dystrophin-positive myofibers from gastrocnemius muscle 
sections immunostained against dystrophin were acquired using a Nikon Eclipse E800 
microscope equipped with a Spot digital camera (Figure 4.2A). Northern Eclipse software 
package (v6.0, Epix Imaging, Inc.) was used to perform dimensional analysis of dystrophin-
positive myofibers both manually and automatically. For manual count, each myofiber was 
numbered and counted using the manual counter provided by the software. For the automatic 
count, the images were converted into binary, black and white (8-bit grayscale) (Figure 4.2B). 
Using a manually-set threshold to delineate the immunofluoresence signal from the background, 
the Northern Eclipse software identifies myofibers that meet the chosen criteria by the user and 
places a circle or a number inside each individual myofiber. The pixel intensities were chosen as 
a set point so that any pixel darker than the set point is turned red/white while pixels lighter than 
the set point are turned cyan/black. The correct set point was determined manually by the user. 
This procedure is called thresholding (Figure 4.2C). During the thresholding, the user should 
maximize the number of connected components so that the myofibers remain distinct enough so 
that the software will be able to count each myofiber separately (Figure 4.3A). If the threshold 
point is at low pixel intensity, the red/white will flood the myofibers (Figure 4.3B), while with 
high pixel intensity, only a few fibers will be distinguished (Figure 4.3C), thereby resulting in a 
low count of myofibers and an under estimation of the data. Increasing the threshold will 
maximize the number of connected components (boundaries around each fiber), and the correct 
number of myofibers will be measured.  The software determines the actual myofiber cross-
sectional area of each fiber and provides quantitative measurements of the number of pixels 
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 occupied by each individual fiber. The fiber area distribution (FAD) of 4000 individual 
myofibers per group was measured by determining the total number of pixels occupied by each 
fiber― a number that was easy to convert to µm2 with analysis software. H&E staining of non-
injected regions of the same grafts was used to detect the boundaries of the host mdx myofibers. 
The parameters such as cross-sectional area, diameter (maximal myofiber length in microns), 
minor axis diameter (the longest line through myofiber that is perpendicular to its orientation) 
and myofiber elongation (ratio of major axis to minor axis) were also calculated as median, 10th, 
25th, 75th, and 90th percentiles (for detailed descriptions of each parameter refer to Appendix C). 
This data was compared with control or between groups, using non-parametric one-way 
ANOVA on ranks with a Dunn’s method for multiple comparisons with an unequal sample size.  
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Figure 4.2 Dimensional analyses of immunohistochemically-labeled dystrophin-positive 
myofibers 
 
 
 
 
 
Figure 4.3 Challenges encountered during thresholding an image 
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 4.11 STATISTICAL ANALYSIS 
 
 
Differences with p < 0.05 were considered statistically significant. All values are given as the 
mean ± standard deviation of the mean (SD). Direct comparisons between treatment and control 
groups were made by using Student’s t test or the Mann-Whitney Rank Sum test (where 
appropriate). Multiple group comparisons were made by using one-way analysis of variance 
(ANOVA). In cases where the data failed this test and indicated that the data varied significantly 
from a population with a normal distribution, nonparametric tests, the Kruskal-Wallis One Way 
Analysis of Variance on Ranks, were used (p<0.05 significance level).  Nonparametric 
distributions were also detected and comparisons were made using Kruskal-Wallis one-way 
ANOVA on ranks with Dunnett’s test for comparing treatment groups with a single control 
group or comparing between groups with an equal number of sample size; or Dunn’s test for 
comparing treatments groups with unequal number of sample size. All statistical testing and 
regression analyses were performed using SigmaStat for Windows Version 2.0 (Copyright 1992-
1995 Jandel Corporation).  
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5.0 RESULTS 
 
 
 
 
5.1 QUANTITATIVE DETECTION OF NGF 
 
 
Two different methods of NGF stimulation were used in this study: retroviral transduction of 
MDSCs with the CL-NGF vector to induce expression of human NGF (E-MDSCs) and direct 
stimulation of MDSCs with NGF protein (100 ng/ml) for 7 days (S-MDSCs). For both groups, 
normal MDSCs that were neither stimulated nor transduced served as controls (C-MDSCs). We 
used ELISA to measure the levels of NGF secreted by MDSCs in vitro. After transduction with 
CL-NGF that carries a 3’ long-terminal repeat (LTR), virus packing signal (ψ), and human NGF 
cDNA driven by the cytomegalovirus promoter (CMV-P), genetically engineered MDSCs (E-
MDSCs) were able to synthesize, process, and secrete active human NGF (Figure 5.1).  
 
 
 
 
 
Figure 5.1 Schematic representation of the retroviral vector expressing NGF  
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Quantitative detection by ELISA of NGF protein within the cell supernatant revealed that 
the level of NGF secreted by E-MDSCs reached 307.4 ± 42.5 ng/106cells/24 hours 3 days after 
transduction and continued to be high 6 and 9 days after transduction (173.2 ± 11.1 
ng/106cells/24 hours and 164.9 ± 28.2 ng/106cells/24 hours, respectively, *p < 0.05). In contrast, 
NGF-stimulated MDSCs (S-MDSCs) and control (non-treated) MDSCs (C-MDSCs) on average 
secreted NGF at barely detectable levels at the three time points (0.09 ± 0.17 ng/106cells/24 
hours and 0.02 ± 0.37 ng/106cells/24 hours, averages for S-MDSCs and C-MDSCs, respectively, 
Figure 15).  
 
 
 
 
Figure 5.2 Quantitative detection by ELISA of the NGF protein in the cell supernatant  
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5.2 PROLIFERATION KINETICS 
 
 
Growth factors stimulate the proliferation of myogenic precursor cells. To investigate the cellular 
response of MDSCs to NGF, we examined cellular division time (DT), and population doubling 
time (PDT). We fit experimental data sets for C-, E-, and S-MDSCs to the Sherley model 
equations by using nonlinear regression with the correlation coefficient R2 > 0.90 to estimate 
mitotic fraction (α) (i.e., the fraction of daughter cells that are actively dividing). Our data 
suggest that the average DTs (C-MDSCs = 11.9 hours, E-MDSCs = 11.5 hours, and S-MDSCs = 
12.1 hours) were not significantly different in the various groups (p = 0.053, Kruskal-Wallis 
analysis on ranks) and that the PDTs of the different cell groups were also quite similar (11–13 
hours). Moreover, we observed a strong association (as indicated by the high correlation 
coefficient) for all of the groups (R2 = 0.99), but no difference in the estimated α for the 3 groups 
(C-MDSCs = 0.94, E-MDSCs = 0.92, and S-MDSCs = 0.94). The mean mitotic fraction 
remained relatively constant among the groups (~0.94) (Figure 5.3). These results indicate that 
neither NGF transduction nor stimulation significantly alters the proliferation kinetics of 
MDSCs. 
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Figure 5.3 Proliferation kinetics of MDSCs 
 
 
 
 
5.3 IN VITRO STEM CELL AND MYOGENIC MARKER PROFILES 
 
 
We investigated the expression levels of the stem cell markers CD34 and Sca-1 by flow 
cytometry. Data were collected by performing logarithmic amplification on 5000 cells, excluding 
cell debris by combining forward and side scatters. This data is presented as dot plots in Figure 
5.4A (the percentage of cells in each quadrant is indicated in the upper right-hand corner). Our 
results indicate high expression levels of the stem cell markers CD34 and Sca-1 (> 70%) by the 
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 control group (C-MDSCs), 7 days after either retroviral transduction of the cells with the CL-
NGF vector (E-MDSCs) or stimulation with 100 ng/ml NGF (S-MDSCs). We observed no 
significant difference between the groups (in terms of stem cell marker expression) after 2 weeks 
of in vitro expansion (p = 0.655). This marker stability suggests that NGF does not affect the 
stem cell marker expression of MDSCs in vitro.  
We also used immunofluorescent staining to assess the cells’ expression of two myogenic 
proteins: Pax-7 and desmin. Myogenic differentiation assay revealed low levels of Pax-7 and 
desmin expression. We quantified the expression of Pax-7 and desmin as the ratio of nuclei 
positive for Pax-7 or desmin to the total nuclei in 10 randomly chosen fields. As shown in Figure 
5.4B, there were no significant differences in Pax-7 expression by the different groups of treated 
and untreated MDSCs (p = 0.148, n=6). Whereas E- and C-MDSCs expressed similar levels of 
desmin, we observed significantly more desmin-expressing cells in the S-MDSC group (p < 
0.05, n=6). 
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Figure 5.4 Marker profile analysis of MDSCs 
 
 
 
 
5.4 IN VITRO MYOGENIC DIFFERENTIATION 
 
 
After cultivating the cells under low-serum and high density conditions, we assessed myogenic 
differentiation in the 3 groups by performing immunohistochemical staining for fast myosin 
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 heavy chain (MHC) expression to analyze myotube formation Representative images of MHC-
positive C-, E-, and S-MDSCs (Cy3; red) overlaid on nuclear counterstain (DAPI; blue) are 
shown in Figures 5.5A–C. We defined differentiation efficiency as the percentage ratio of MHC-
expressing nuclei to total number of nuclei. C-MDSCs consistently showed a differentiation 
efficiency of 35%, and E-MDSCs showed 30% differentiation efficiency. In contrast, the 
differentiation efficiency of S-MDSCs, 26%, was significantly lower than that of C-MDSCs, 
which indicates that S-MDSCs have a decreased ability to fuse and form multinucleated 
myotubes (*p < 0.05, n=3, Figure 5.5D). Scale bar represents 100 µm. 
 
 
 
 
D 
 
 
Figure 5.5 Myogenic differentiation in vitro 
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5.5 MUSCLE REGENERATION 
 
 
We evaluated the ability of the 3 groups of cells (E-, S-, and C-MDSCs) to regenerate dystrophic 
skeletal muscle by transplanting 3x105 cells from each cell group into the gastrocnemius muscles 
of 8-week-old male mdx mice. Fourteen days after transplantation, we sacrificed the animals; we 
harvested the injected gastrocnemius muscles, snap froze them, and sectioned them using a 
cryostat. Using immunohistochemical staining, we assessed the number of dystrophin-positive 
myofibers with manual count and quantitated muscle regeneration in terms of the regeneration 
index (RI: the number of dystrophin-positive fibers in the host muscle per 105 donor cells). The 
dystrophin-positive grafts of E- and C-MDSCs are shown in Figures 5.6A and 5.6B. The average 
RI of E-MDSCs was significantly larger than that of C-MDSC’s (435.6 ± 85.5 vs. 197.5 ± 53.8, 
*p < 0.001, n=8, Figure 5.6C). Scale bar represents 250 µm. 
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Figure 5.6 Dystrophin-positive myofiber regeneration elicited by MDSCs transduced with 
CL-NGF 
 
 
 
Differences in the size of the dystrophin-positive grafts generated by S-MDSCs vs. C-
MDSCs were even more dramatic, as shown in Figures 5.7A and 5.7B, respectively. Our 
analysis revealed that the average RI of S-MDSCs was 3-fold higher than that of C-MDSCs (852 
± 203.3 vs. 266.8 ± 137.4, < 0.001, n=11, Figure 5.7C). In addition, the RI of S-MDSCs was 
statistically higher than that of E-MDSCs (*p < 0.001). Scale bar represents 250 µm. 
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Figure 5.7 Dystrophin-positive myofiber regeneration elicited by MDSCs stimulated with 
NGF protein 
 
 
 
 
5.6 MORPHOLOGICAL ANALYSIS 
 
 
Cell morphology was qualitatively examined from the time-lapsed images obtained from the 
bioinformatic cell culture system (200x magnification) during expansion. An example of such 
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 images at 0-96 hour’s intervals is shown in Figure 5.8. It is apparent that the morphology of the 
cell population in all three groups is heterogeneous, containing mainly small round shape, with 
some well-defined spindle-shaped cells also being observed.  
 
 
 
 
 
Figure 5.8 Representative time-lapsed images of C-MDSCs population demonstrating 
visualization and morphological recognition of cell morphology in culture (refer to attached 
video clip by double clicking on first image) 
 
 
 
Quantitative analysis of fiber area distribution (FAD) was evaluated using the same 
immunohistochemical engraftment that was used to calculate the RI. FAD analysis of grafts 
generated by the 3 groups of MDSCs revealed that more than 50% of the total number of 
dystrophin-positive myofibers in each group had areas of 0–100 µm2.  In this range, no 
statistically significant differences existed among the treatment groups compared to C-MDSCs 
(p = 0.678; Figure. 5.9). We also analyzed non-injected areas of mdx muscle and found that most 
of the myofibers had areas > 1000 µm2. A non-parametric distribution weighted toward smaller 
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 myofiber sizes was apparent. These findings indicate that C-, E-, and S-MDSCs all generated 
new dystrophin-positive myofibers, as indicated by their small size and centronucleation (Figure. 
5.10, arrow). Scale bar represents 50 µm. 
 
 
 
 
 
Figure 5.9 Fiber area distribution (FAD) of newly generated (dystrophin-positive) and host 
myofibers 
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Figure 5.10 A high magnification image of a small portion of an E-MDSC graft shows a large 
number of centronucleated myofibers 
 
 
 
Quantitative measurement of other morphometric parameters such as cross-sectional area, 
diameter, minor axis diameter, and myofiber elongation were also measured and compared based 
on the same images used to calculate RI. Figure 5.11 illustrate the myofiber measurement using 
box plots with median, 10th, 25th, 75th, and 90th percentiles as vertical boxes for each parameter 
mentioned above. Dystrophin-positive myofibers generated by E-, S-MDSCs groups showed a 
statistically greater median values for area, diameter, perimeter, minor axis diameter when 
compared to C-MDSCs (p < 0.05) indicating accelerated muscle fiber regeneration. Median 
cross-sectional area: C-MDSCs (63.2 µm2), E-MDSCs (112.8 µm2), S-MDSCs (95.3 µm2). 
Median diameter: C-MDSCs (14.4 µm2), E-MDSCs (19.7 µm), and S-MDSCs (17.3 µm). 
Median minor axis diameter: C-MDSCs (7.7 µm2), E-MDSCs (11.5 µm), and S-MDSCs (9.6 
µm). Elongation: C-MDSCs (1.7), E-MDSCs (1.7), and S-MDSCs (1.7).  The elongation 
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 parameter (the ratio of the major axis of the myofiber to of its minor axis) between the groups 
did not differ, thereby showing the same physical morphology of myofibers in all the groups 
(Table 5.1). 
 
 
 
 
 
Figure 5.11 Morphological features of dystrophin-positive myofiber 
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Table 5.1 Dimensional characteristics of dystrophin-expressing myofibers 
 
 
 
Area (µm2) 
 
 
Elongation  
 
Median
 
Percentiles 
25%-75% 
 
Median
 
Percentiles 
25%-75% 
 
Mdx 
(non-injected) 
 
2390.3 
 
 
1481 – 3724.8
 
1.7   
 
1.4 – 2.2 
 
C-MDSCs 
 
63.2 
 
33.9 – 155.8 
 
1.7 
 
 1.4– 2.1 
 
E-MDSCs 
 
112.8 
 
48.9 – 288 
 
1.7 
 
1.4 – 2.2 
 
S-MDSCs 
 
95.3 
 
44.9 – 234.5 
 
 1.5  
 
1.3 – 1.7 
 
 
Diameter (µm) 
 
 
Minor Axis Diameter (µm) 
 
 
Median
 
Percentiles 
25%-75% 
 
Median 
 
Percentiles 
25%-75% 
 
Mdx 
(non-injected) 
 
14.4 
 
10.6 – 22 
 
7.7 
 
5.8– 12.5 
 
C-MDSCs 
 
19.7 
 
12.5 – 29.7
 
11.5 
 
7.3 – 17.7 
 
E-MDSCs 
 
17.3 
 
11.5 – 26.8
 
9.6 
 
5.8 – 15.3 
 
S-MDSCs 
 
71.8 
 
57.4 – 92.9
 
48.8 
 
38.3 – 62.2 
 
 
 
At last, the method of manual and automatic count of dystrophin-positive myofibers were 
compared between engraftments obtained from all the groups. While small engraftments were 
easily analyzed with the automatic count, the larger engraftments were challenging. The percent 
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 difference between the manual and automatic count were on average 12.4% for small 
engraftments (C-MDSCs) and increased to 23.6-44% for larger engraftments (E-MDSCS and S-
MDSCs, respectively) showing an underestimation of myofiber counts by automatic analysis. 
This is more likely due to loss of resolution in larger engraftments at the edges where the images 
are merged (Figure A.2, Appendix C), and also higher numbers of small, newly generated 
myofibers that are difficult for the software to detect. 
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6.0 DISCUSSION 
 
 
 
 
Although the precise role that NGF plays in the different steps of muscle regeneration remains 
largely unknown, our observations indicate that NGF can improve the regeneration ability of 
MDSCs in skeletal muscle of mdx mice. Whereas the results of our in vitro experiments 
demonstrate that neither retroNGF transduction nor direct stimulation with NGF protein changes 
the marker profile of MDSCs or their proliferation dynamics, direct stimulation with NGF 
protein appears to delay the myogenic differentiation of MDSCs.  
It is well documented that the process of muscle regeneration in normal and dystrophic 
muscle depends on locally produced cytokines and growth factors [111, 121, 125, 184]. Skeletal 
muscle injuries induce a well-established sequence of cellular events that result in the release of 
growth factors that stimulate quiescent satellite cells and other muscle precursor cells to enter the 
cell cycle, proliferate, and eventually fuse to form newly regenerated myofibers and restore 
muscle architecture [167, 185]. Some studies suggest that NGF, the best characterized 
neurotrophic factor, plays an important role in restoring innervation in many tissues after injury. 
For example, NGF is integral to the survival of sensory and peripheral neurons that control 
contraction of smooth muscle [186-188] and axonal regeneration in skeletal muscle [189].  
A prior study in our lab has shown that MDSCs stimulated with NGF or vascular 
endothelial growth factor (VEGF) differentiated toward nerve and endothelial lineages, 
respectively, in a more effective manner when compared with non-stimulated cells. This was 
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 evident by a greater number of cells expressing 2’,3’-cyclic-nucleotide 3’-phosphodiaesterase 
(CNPase), a myelin-associated enzyme, and von Willebrand Factor (vWF), an endothelial cell 
marker [96]. These findings suggest that the release of local environmental cues (i) can trigger 
the differentiation of muscle stem cells toward non-myogenic lineages after transplantation of the 
cells into dystrophic muscle and (ii) may contribute to the regeneration of functional muscle 
tissue by enhancing vascular and neuronal supplies.  
Here, we investigated whether MDSCs retrovirally transduced to express NGF display 
different proliferation behavior or altered myogenic differentiation in vitro and improved muscle 
regeneration of dystrophic muscle in vivo.  We used MDSCs rather than satellite cells because 
the former exhibit a superior transplantation capacity and the ability to undergo multilineage 
differentiation [96, 103]. The ex vivo gene transfer approach enables constant delivery of lower, 
more physiological doses of proteins that, if delivered by direct injection, would be quickly 
degraded by natural processes. Retroviral vectors transduce dividing cells with high efficiency 
[190] and elicit long-term, stable expression of the gene of interest by integrating into the host 
cell genome; such vectors are already being used in clinical settings [191, 192]. Our results 
indicate that MDSCs transduced with a retrovirus vector continuously delivered high levels of 
NGF for up to 9 days in culture, while maintaining their typical stem cell marker profile (CD34 
positive and Sca-1 positive). After injection into the skeletal muscle of mdx mice, E-MDSCs 
proliferated and differentiated to generate new muscle fibers that formed large grafts by as early 
as 14 days. These data suggest that the expression of NGF by retrovirally transduced MDSCs is 
relatively stable in vivo and may enhance MDSCs’ survival at the muscle regeneration site.  
In spite of what we have hypothesized in our specific aim 1, the proliferation dynamics of 
the treated MDSCs, including PDT, DT, and α, were similar regardless of the treatment method 
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 (i.e., stimulation or transduction). However, S-MDSCs exhibited higher regeneration efficiency 
in vivo than E-MDSCs or C-MDSCs, perhaps due to the delayed differentiation of S-MDSCs 
caused by NGF stimulation in vitro. Some research suggests that cells with delayed fusion 
characteristics have increased regeneration capacities [103]. This could explain our observation 
that S-MDSCs differentiated into myotubes more slowly than did C- and E-MDSCs in vitro and 
exhibited the greatest regeneration efficiency in vivo. It is feasible that the higher proliferation 
ability of S-MDSCs before fusion in vivo allowed them to remain in an undifferentiated state 
longer, thereby resulting in enhanced regeneration. It should be noted that NGF in target tissues 
is in the subpico-molar range [193, 194]. Consequently, it is likely that high levels of NGF 
expression such as in the E-MDSCs, reflect changes such as down regulation of TrkA and 
p75NTR receptors that can diminish the overall binding affinities for NGF. 
Our currently-used methodology measures the dystrophin expression of transplanted cells 
participating in the regeneration process as a whole, including both the conversion of already 
existing myofibers, through donor-host fusion, as well as the formation of new myofibers from 
donor-host and donor-donor cell fusion.  One indirect way to assess these differences of the 
probable route taken by the injected cells (i.e. new myofiber formation), is the fiber area 
distribution (FAD) of dystrophin myofibers relative to those of the control non-injected muscle. 
The FAD showed that most of the individual dystrophin-positive myofibers in all of the MDSC 
groups had areas of 0–100 µm2, whereas most of the host mdx myofibers had areas of > 1000 
µm2. Furthermore, nuclear staining with DAPI revealed that most of the small myofibers 
observed in the MDSC grafts were centronucleated. In combination, these results suggest that 
injection of C-, E-, or S-MDSCs led to the formation of new dystrophin-positive myofibers via 
the fusion of the donor cells with one another rather than the fusion of donor cells with host 
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 muscle fibers. Recent studies conducted by Toti et al. 2003 [195] show that only regenerated 
myofibers in the muscles of DMD patients consistently express NGF; dystrophic myofibers or 
healthy myofibers do not show NGF immunoreactivity. In addition, the authors report that 
regenerated myofibers in muscle biopsies from DMD patients are small, round, and occur mostly 
in clusters. These observations led them to hypothesize that in addition to its autocrine function, 
NGF exhibits a paracrine effect on neighboring regenerated myofibers. Our observations of 
myofibers generated by MDSCs transplanted in the skeletal muscle of mdx mice, particularly E-
MDSCs, suggest a similar phenomenon. 
It is worth mentioning that the method of evaluating muscle regenerative efficiency was 
assigned through manually counting dystrophin-positive myofibers on only sections of muscle 
with the largest engraftment as opposed to accounting for the area occupied by the myofibers and 
thus providing only a two-dimensional view of the regenerative process. This current method of 
quantifying dystrophin expression measures only local dystrophin expression, while ignoring the 
distribution of dystrophin-positive myofibers across the entire gastrocnemius muscle. It would be 
extremely difficult and time consuming to quantify the dystrophin-positive myofibers in the 
entire length of the muscle. Therefore, sophisticated image analysis software is needed with 
three-dimensional reconstruction to account for dystrophin-positive expression across the entire 
muscle. This would be practical for larger-scale studies with multiple group comparisons such as 
those being performed here.  
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7.0 FUTURE STUDIES 
 
 
 
 
Aside from those studies already mentioned within previous sections, further experimentation is 
necessary in order to confirm the evidence presented here. In addition, more specific studies to 
address the underlying mechanisms of NGF action in muscle regeneration that would build upon 
and presumably strengthen the work herein presented are also needed. As a follow-up to the 
work described here, experiments will be conducted to further investigate the role of NGF 
stimulation mediating MDSCs’ survival or promotion of cell death to explain the myogenic 
differentiation status and regeneration capacity. When placed in vitro, expansion and/or 
activation of quiescent progenitor populations may likely occur due to growth factors’ effect. 
This may have important implications in terms of regeneration due to direct participation or the 
cells’ chemoattractant abilities. The differences of cell survival and proliferation of MDSCs 
injected into the skeletal muscle may in part explain our improved outcome in regeneration 
capacity of stimulated versus non-treated MDSCs. To test this assumption, TUNEL assay can be 
used to determine differences in the number of apoptotic cells at the site of transplantation 
following injection. Apoptotic cells are revealed by using a fluorescence-conjugated dUTP to 
label the 3’ ends of the DNA fragment generated by activated endonucleases.  One can also 
investigate the actively-dividing cells within injected muscle by tracking the BrdU-labeled cells 
as representative of the mitotically active cells versus apoptotic cells at the site of injection.  
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 A number of groups have recently shown that Akt expression, a prosurvival protein, plays an 
important role in myoblasts survival [196] via p75NTR , the low affinity receptor of NGF. The 
p75NTR mediated signals are biologically important for the normal muscle development, since the 
absence of p75NTR receptor in mutant mice showed an impaired muscle strength [196]. Since Akt 
is known to mediate cell survival, and p75NTR activation can promote phosphorylation of Akt, we 
postulate that Akt is activated by NGF via p75NTR to promote the survival of the MDSCs and 
their transition into differentiated states. It was just reported by Shailaja et al. 2005 [196] that 
endogenous activation of Akt is most likely mediated by secreted NGF, and the significance of 
the autocrine signaling by NGF is underscored by its down regulation prior to differentiation 
[170]. So, we predict that the endogenous Akt activation is most likely due to expression of NGF 
by the engineered and stimulated MDSCs with NGF and its subsequent autocrine signaling.  
It should be emphasized that high level of NGF may reflect changes in the levels of 
p75NTR expression at different stages of myogenesis. As a follow-up to the work described here, 
experimentation has already been initiated to further investigate the receptor levels in culture 
after NGF stimulation. To determine if Akt expression plays a role in the improved 
transplantation capacity of E- and S-MDSCs compared to C-MDSCs, levels of Akt should be 
monitored. Protein extract will be prepared for Western blot analysis using manufacturer 
recommendations with antibodies against Akt and phosphorylated Akt on the Ser 473 (Cell 
Signaling Technology, Beverley, MA). The Akt kinase activity will be measured using the Akt 
Kinase Assay Kit using GSK-3 α/β fusion protein as a substrate on immunopercipitated Akt 
(Cell signaling Technology, Beverley, MA). We believe that these future experiments may 
provide evidence elucidating the signaling mechanisms and providing a linkage between the in 
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 vitro settings within the context of muscle regeneration. This will offer insight into our current 
understanding of the underlying factors that promote muscle regeneration versus atrophy. 
The formation of newly regenerated dystrophin-positive myofibers in dystrophic skeletal 
muscle does not always correlate with the physiologic performance in the injured muscle, and 
effective healing, however, involves the combination of both measures. In this regard, 
independent confirmation of physiologic measurements (e.g. contractile properties of muscle) 
should be performed before any conclusions regarding the long-term outcome and functionality 
of regenerated muscle fibers can be made. The gastrocnemius muscle should be studied under 
isometric conditions in order to assess specific force generation. In addition, repetitive 
lengthening actions, i.e. “eccentric contraction,” should be undertaken in order to assess the 
ability of regenerated muscle to resist contraction-induced decreases in force output. Unlike 
DMD patients, mdx mice exhibit a mild phenotype partially because of higher expression of 
utrophin, a protein closely related to dystrophin [197, 198] that partially compensates for lack of 
dystrophin [36, 199]. Indeed, double mutant mice mdx/utr -/- lacking both dystrophin and 
utrophin genes develop severe muscular dystrophy and die prematurely [200, 201], similar to 
outcomes observable in DMD patients. Therefore, designing a better model to study contractile 
properties of the muscle is currently in demand and under investigation. 
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8.0 SUMMARY AND CONCLUSIONS 
 
 
 
 
Growth factors play important roles as signaling molecules throughout postnatal development, 
adult life, and aging. This study investigated the effect of nerve growth factor (NGF) on the 
muscle regeneration of the skeletal muscle of dystrophic (mdx) mice. Transplantation of muscle-
derived stem cells (MDSCs) either stimulated with or genetically engineered to express NGF 
resulted in the regeneration of significantly more dystrophin-positive myofibers than did 
transplantation of control (non-treated) MDSCs. NGF did not alter the marker profile or 
proliferation behavior of MDSCs; however, MDSCs stimulated with NGF exhibited delayed in 
vitro differentiation, which may at least, partially explain their improved regeneration capacity 
observed in vivo. 
In conclusion, these findings underscore the importance of NGF during skeletal muscle 
tissue remodeling and indicate that this molecule can improve the muscle regeneration capacity 
of muscle stem cells. Additional studies focused on NGF will substantially enhance our 
understanding of its mechanism and, in so doing, may lead to the development of alternate 
strategies for the treatment of DMD and other muscular dystrophies. 
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APPENDIX A 
 
 
 
 
PREPLATE TECHNIQUE: ISOLATION OF THREE POPULATIONS OF MUSCLE-
DERIVED CELLS 
 
 
Gastrocnemius muscles of several adult-aged normal mice (3 weeks of age, C57 BL/10J; Jackson 
Laboratories) were obtained under aseptic techniques.  A single cell suspension was obtained by 
digestion and enzymatic dissociation of combined muscles to obtain the appropriate number of 
cells. Enzymatic dissociation was performed by serial digestion of hand-minced muscles in 0.2% 
(by weight) collagenase-type XI solution (Sigma) for 1 hour, 0.3% dispase (Gibco-BRL) for 45 
minutes, and 0.1% trypsin (Life Technologies) for 30 minutes.  The final cell suspension was re-
suspended in serum-supplemented Dulbecco’s modified Eagle’s medium (DMEM, containing 
10% fetal bovine serum, 10% horse serum, 0.5% chick embryo extract by volume, and also 100 
U/mL penicillin and 100 µg/mL streptomyocin; Gibco-BRL), which was also used for 
subsequent culturing, and added to a T-75 collagen-coated flask (collagen Type I, Sigma). After 
2 hours, floating cells contained within the supernatant were removed and transferred to a second 
T-75 flask.  Fresh medium was added to the first set of adherent cells (termed preplate 1, or 
PP1), and this procedure was continued for PP2 through PP6 at subsequent 24 hour periods.  A 
smaller surface area flask, T-25, was used for PP6 as the number of remaining non-adherent cells 
by this point was comparatively lower. This process resulted in six primary cultures of adherent 
cells with increasing initial adhesion times that are highly fibroblastic in nature [95, 202-204] 
that were subsequently used for surface protein and desmin analysis. Based on previous reports 
[95], the non-myogenic cells in pp2 and pp3 were removed from the cultures by replating the 
cells. The resulting enriched pp2 and pp3 desmin [+] cells were combined with pp4 and pp5 cells 
and were termed “early preplate cells” (EP). Cells in the pp6 cell population took an additional 
24–72 h to attach to collagen-coated dishes after transfer from pp5 and were termed “late 
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 preplate cells” (LP). Most of the LP cells died during the first 1–2 wks of the cultivation period, 
with very few of the adherent surviving cells proliferating and forming clonal colonies that are 
called “long-term proliferating” (LTP) cells or muscle-derived stem cells (MDSCs). A flow chart 
for the isolation of different population of muscle-derived-cells (EP, LP, and LTP or MDSCs) 
based on their adhesion characteristics to collagen coated flasks are shown below (Figure A.1).  
 
 
 
 
pp1 
 
 
 
Figure A. 1 Schematic diagram of the preplating technique used for the isolation of muscle-
derived cell population 
2 hrs
24 hrs 
pp2 
24 hrs 
pp3 
24 hrs pp4 EP 
24-72 hrs pp5 
pp6 
LP LTP (MDSCS) 
1-2 wks 
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APPENDIX B 
 
 
 
 
NON-EXPONENTIAL GROWTH MODEL 
 
 
Mathematical growth models are necessary tools that play a key role in characterizing and 
measuring the kinetic parameters of stem cell populations and understanding stem cell dynamics. 
Within heterogeneous stem cell populations such as MDSCs, a fraction of the cell population 
often remains in a non-dividing state.  To account for this fraction in describing cell population 
growth, a non-exponential growth model has been proposed by Sherley [180]. To simplify the 
mathematical description of non-exponential growth, the following assumptions are made: 1) 
cells undergo asymmetric divisions, such that dividing cells are capable of giving rise to both 
dividing and non-dividing cells; 2) DT of the mitotically-active fraction remains constant; and 3) 
non-dividing cells do not re-enter the cell cycle.  The validity of these assumptions has been 
discussed within the myogenic cell compartment [181].  Starting with an initial number of cells, 
N0, the number of cells at any subsequent doubling time interval can be described by the 
following equation: 
 
oo NNN )1(21 αα −+=  
 
where the first term represents the mitotically-active fraction (assuming the cells split to 2 
daughter cells) and the second term represents the non-mitotically-active (non-dividing) fraction.  
Using the assumption that daughter cells that are dividing remains constant, such that at time 
interval = 2, we have 
 
ooo NNNN )1()2)(1()2(22 ααααα −+−+=  
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or 
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Expansion of the terms and simplification leads to the following expression 
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Now, if we define i = any positive value t/DT, and apply the identity, we have the following 
equation: 
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where the cell number, N, at any time, t, depends on: 1) the initial number of cells (N0), 2) the 
division time (DT) (FD and GT, respectively in Sherley et al.) and 3) the mitotic fraction (α) or 
the fraction of daughter cells which are actively dividing. The Sherley model [180] includes a 
parameter that accounts for the presence of non-dividing cells (quiescent or senescent cells): 
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Here, we can see that if α= 1, the equation reduces to the general exponential 
equation . As α approaches 0.5, the model equation becomes t/DT  NN 20= DTtN  NN  200 +=  
and there is linear growth with a slope of N0/2DT.  
 
It should be recognized that the phrases ‘division time’ and ‘doubling time’ are not equal 
(DT≠ PDT) [181]. Simply, division time (DT) should be understood as to the time that it takes 
for an individual cell to complete the cell cycle (cytokinesis) and doubling time, or more 
correctly population doubling time (PDT), is defined as the time it takes for a population of cells 
to double. 
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If all cells in a given population are mitotically active then, PDT=DT, however, if there 
are non-mitotic cells present within the population then PDT∫DT. When non-dividing cells are 
present, the population doubling time is necessarily slower than the division time. 
The appropriate equation to use to estimate PDT is as follows: 
 
( )t/PDT
0 2 NN =  
 
where N is the number of cells at time t, and N0 is the initial number of cells and PDT is the 
population doubling time.  
 
This comes from the more general exponential equation: 
 
kt
0 e NN =  
 
to get the number of population doubling time, use the following equation: 
 
PDT
t doublings # =
 
 
(e.g. if PDT = 10 hrs, then at time t = 24 hrs, you have 2.4 population doublings). When solving 
the first equation above for t/PDT: 
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 as a result, 
 
 
0
2 N 
Nlogdoublings population of# =
 
 
The Sherley model [180] equation can be used to obtain PDT based on mitotic fraction, α, and 
DT by setting the PDT as the time t, where N=2N0  and  
 
⎥⎦
⎤⎢⎣
⎡ −= 1
)ln(2
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α
 
 
Here, it is observed that population doubling time is now more accurately represented as a 
function of both α and DT.  
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 Nonlinear Regression  
 
[Parameters] 
F=1 
[Variables] 
Nexp=col(2) 
t=col(1) 
[Equations] 
GT=cell(3,1) 
n=cell(2,1) 
ep=(t/GT)+1 
A=1-(2*F)^ep 
B=2-4*F 
N=n*(0.5+(A/B)) 
fit N to Nexp 
[Constraints] 
F>0 
F<1 
[Options] 
 
 
 
C-MDSCs 
 
R = 0.999 Rsqr (R2) = 0.999  Adj Rsqr = 0.999 
 
Standard Error of Estimate = 5.896  
 
  Coefficient StdError  t  P  VIF   
F  0.945   0.00205  460.722  <0.001   1.000   
 
Analysis of Variance 
   DF SS  MS  F  P 
Regression  0 189225.058 189225.058 5442.733 >1e20 
Residual   6 208.599  34.767   
Total   6 189433.657 31572.276   
 
 
Normality Test: Passed (P = 0.385) 
 
Constant Variance Test: Passed (P = 0.054) 
 
Power of performed test with alpha = 0.050: 1.000 
 
Parameter Value   Std.Err  CV(%)  Dependencies 
alpha   9.447e-1   2.050e-3  2.171e-1 -0.0000000 
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 E-MDSCs 
 
R = 0.997 Rsqr (R2) = 0.995  Adj Rsqr = 0.995 
 
Standard Error of Estimate = 5.896  
    
Coefficient StdError  t  P  VIF   
F  0.923   0.00417  221.435  <0.001   1.000   
 
Analysis of Variance: 
   DF SS  MS  F  P  
Regression 0 195489.727 195489.727 1182.230 >1e20  
Residual   6 992.141  165.357   
Total  6 196481.867 32746.978   
 
    
Normality Test: Passed (P = 0.278) 
 
Constant Variance Test: Passed (P = 0.006) 
 
Power of performed test with alpha = 0.050: 1.000 
 
Parameter Value  StdErr  CV(%)  Dependencies 
alpha   9.231e-1  4.1690e-3  4.516e-1 -0.0000000 
 
 
 
S-MDSCs 
 
R = 1.000 Rsqr (R2) = 1.000  Adj Rsqr = 01.000 
 
Standard Error of Estimate = 2.924 
 
  Coefficient StdError  t  P  VIF   
F  0.936   0.00115  816.573  <0.001   1.000   
 
Analysis of Variance: 
   DF SS  MS  F  P    
Regression 0 151290.897 151290.897 17700.377 >1e20 
Residual  6 51.284  8.547   
Total  6 151342.181 25223.697   
  
Normality Test: Passed (P = 0.233) 
 
Constant Variance Test: Passed (P = 0.014) 
 
Power of performed test with alpha = 0.050: 1.000 
 
Parameter Value  StdErr  CV(%)  Dependencies 
alpha   9.358e-1 1.146e-3  1.225e-1 -0.0000000 
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APPENDIX C 
 
 
 
 
DYSTROPHIN-POSITIVE MYOFIBERS ANALYSIS USING NORTHERN ECLIPSE 
 
 
 
 
 
 
 
All images from the Northern Eclipsed software are reproduced with permission from The Empix 
Imaging, Inc. 
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Images of dystrophin-positive engraftment were taken using the Northern Eclipse 
software. If there was more than one image captured from the engraftment, the images were 
connected so that all positive fibers were measured only once. Figure A.2 shows a composites 
made in Adobe Photoshop 6.0 from all of the images taken from the engraftment of 
gastrocnemius muscle of an mdx mouse injected with MDSCs stimulated with NGF.  
 
 
 
 
 
Figure A. 2 A composite of images from S-MDSCs muscle engraftment  
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Calibrate for Distance  
 
Capturing a picture with known dimensions and then calibrating the software to those 
dimensions is known as calibration. The system is designed to calibrate pixel measurements to 
any unit value (i.e., microns, millimeters, and centimeters). For our purpose, we used an accurate 
glass scale with microns as the unit value. 
An image captured from a scale is shown below (Figure A.3). In the example noted, a 
picture of a micrometer slide was captured from a Nikon microscope using a 40x objective. The 
line was draw such that the starting point is at the top of one scale line and the ending point is at 
the top of the finishing scale line. Then the information such as the objective, the number of units 
that represent the length of the line, and unit name was entered and saved. This procedure was 
done for all of the objectives that were used during the experimental analysis (e.g. 10x, 20x, 40x, 
60x). 
 
 
 
 
40x 
 
Figure A. 3 Image Calibration using micrometer slide with known dimensions 
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Convert To 8-bit Gray 
 
This function is used to convert the current image into 8-bits per pixel image (1 plane of 8-bit 
grayscale data). When the image source is in color, the color data is converted into an image with 
grayscale value. This makes the image ready for thresholding. 
In Toolbar under Process, choose Conversions, and then Convert to 8-bit grayscale.  
Bit is the smallest unit in a binary number (binary digit) or the smallest unit of digital 
information recognized by a computer, and it may take the value of either zero or one (i.e. TRUE 
or FALSE, ON or OFF, 0 or 1, BLACK or WHITE, etc.). A pixel is represented by one or more 
computer bits and is the smallest spatially-digitized unit of an image.  A single pixel has a single 
gray or color value, it is the smallest units by which the image can be collected and displayed. 
The sum of bits per pixel directly determines the number of colors or gray levels that can be 
represented. An 8-bit (1byte) image contains 28 or 256 gray levels, usually from zero (black) to 
255 (white).   
 
Data Options   
 
In the Toolbar menu under Measure, choose Data Options. This menu allows for choosing 
methods of object exclusion or inclusion during measuring, morphometric data reporting 
choices, levels of data reporting, pixel exclusion, numeric data hole filling, and morphometric 
boundary options (Figure A.4). 
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Figure A. 4 Northern Eclipse Data Options window 
 
 
 
Object Policies 
Cut by Selection: if the desired area is already selected by Trace Tool such as Rectangle Tool, 
this option actually cuts objects under traced areas during measuring (Figure A.5A). This 
selection measures all objects within the traced area and cuts objects along the trace line 
measuring partial objects along the cut line.  The Cut by Selection option should be turned on if 
no thresholding is done prior to measuring.  
Excluded from Selection: excludes all objects touching the lines of any traced areas during 
measuring (i.e. only measuring objects totally within traced areas) (Figure A.5B). 
Included in Selection: includes all objects inside a traced area. Those objects touching the 
traced area are not counted (Figure A.5C). 
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 Included/Excluded according to Centroid: is the most statistically correct method of counting 
or measuring objects, because only objects with a Centroid (center of gravity point) inside the 
traced region are included in the count (Figure A.5D). 
 
 
A   B   C   D 
 
 
Figure A. 5 Northern Eclipse method of object exclusion or inclusion 
 
 
 
Hint: Cut by Selection is generally not used for counting, but it can be very useful for 
densitometry or for objects that are not easy to threshold and therefore must be traced.  
In all our measurements, we used Excluded from Selection, so only the myofibers totally within 
traced areas were measured. 
 
 
Morphometric Parameters 
 
The type of data to be recorded can be selected by double clicking on or off the red check marks 
beside the list of morphometric parameters.  
 
For our purpose of myofiber area distribution, we used 3 groups of parameters: 
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 Group 1: Area & Perimeter 
 
Primitives: 
Area The total number of pixels that an object occupies (Figure A.6A). 
Group 2: Enclosure & Orientation 
 
Primitives: 
Diameter The longest line through an object that is parallel to its orientation (Line KL) 
(Figure A.6B). 
Minor Axis Diameter The longest line through an object that is perpendicular to its 
orientation. (Line HJ) (Figure A.6B). 
Derived: 
Elongation Diameter / Minor Axis Diameter.  Provides a general idea of object proportions 
independent from perimeter or shape (Figure A.6B). 
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BA 
 
Figure A. 6 Northern Eclipse morphometric parameters 
 
 
 
Group 3: Other Parameters 
Object # A unique number that refers to the number of objects being counted. In our case, 
object # is the number of dystrophin-positive myofibers. 
Units The units of the calibrated measurements. Our unit of calibration is microns. 
Bin Classification The name of the Bin that an object is classified as. We created a new bin 
named “myofiber analysis”. 
Boundary 
This option allows the choice of an 8-way Connected or 4-way Connected morphometric 
measuring algorithm to be used. The Boundary method will be required by the user to determine 
when very thin, ambiguous objects need to be deciphered. 
 
 
81 
  
Bin Classifier Options  
In Tool bar under Measure choose Bin Classifier Options. 
Binning is a method of including or excluding certain objects by means of the objects 
morphometric characteristics (e.g. area, perimeter, and shape factor). Sorting, or data exclusion, 
takes place during the object measurement operations with the goal of selecting or rejecting 
objects that fall into preset morphometric ranges (e.g. measure all objects greater than 500 
microns, or measure all objects with a shape factor greater than 0.7 etc.). We added two new bins 
referred to as “small fibers” and “large fibers” (Figure A.7). 
 
 
 
 
 
Figure A. 7 Northern Eclipse Bin Classifier Options 
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For large Fibers: 
 
Area  <  2000 
Area  >  500 
 
For small fibers: 
 
Area  ≤  500 
Area  > 20 
 
We checked the Include these Objects check box so that all the data with new bin category 
criteria will be included. We un-checked the Default Bin so that other parameters would not be 
included in our measurements.  
 
Note: The above numbers were modified for each engraftment based on the quality of the image 
and fiber size distribution. 
 
 
Threshold   
 
This function is used to select objects in an image by specifying range(s) of values that 
differentiate it from the rest of the image. This process is alternatively known as binarization, 
segmentation, or object detection.  Each pixel is tested independently and it is either selected or 
rejected according to the same criteria.  The goal is to adjust the range(s) only until the pixels in 
the object are selected.  This happens differently depending upon whether the image is 
monochrome or color. 
A range of intensities that corresponds to the gray values in the object can be chosen so 
that the gray values can be seen in the main status bar by moving the mouse over the image 
before calling this function.  The display will change as the values are adjusted, showing the 
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 selected pixels in red/white and the unselected pixels in cyan/black.  The range will be between 0 
and 255 for 8-bit images and 0 to 65535 for 16-bit images.   
Occasionally, the range that selects the desired object also selects debris or unwanted 
objects.  If they are smaller, larger, or have a different shape than the desired criteria, then bin 
classification can be used to classify and not include those objects that fall within that bin.  
Alternatively, the objects can be classified so that objects that do not fall within the created bin 
are not included. Finally, the unwanted objects can be ignored and deleted if necessary.  
 
 
Measured Selected Objects   
 
The last step is measuring selected objects and obtaining the raw data. An example of our raw 
data created in the Data Results window is shown below in Figure A.8. 
 
 
 
 
 
Figure A. 8 Northern Eclipse Data Results window  
 
 
 
The count values were logged to an Excel spreadsheet by clicking on Log to DDE. Data 
was analyzed on the selected parameters and statistical analysis was performed as previously 
described.  
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APPENDIX D 
 
 
 
 
PROCEDURES FOR QUANTIZATION OF DYSTROPHIN-POSITIVE MYOFIBER 
USING NORTHERN ECLIPSE 
 
 
1. Open Northern Eclipse 
2. Open your saved image (TIFF format) 
3. In Toolbar choose Process 
→ Conversion 
    → Convert to 8-bit grayscale 
4. In Toolbar choose Measure 
→ Calibrate for distance 
Note: Select the right calibration from the already calibrated scales. If the image is taken 
with a different microscope (e.g. Nikon or Leica), make sure that the correct calibration is 
chosen. In order to check the microscope used to take the image, right click on image and click 
on Image Info. Look at dimensions and consider the following points: 
 
If the dimension is 1280x1024, the image has been taken on Lecia with the Retiga 1300 camera. 
Consequently, choose calibration for Leica. 
 
If the dimension is 1360x1024, the image has been taken in Nikon with the Retiga Exi camera. 
Here, choose calibration for Nikon. 
5. Setting up the parameters 
A)  Go to “View” 
→ View Options  
    → “Data” tab  
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Object Policies 
 
Select Objects Partially inside selected are  Cut by Selection 
 
Object under 10 pixels in size are discarded  
(This options is for eliminating debris or not defined fibers due to their small size, so the # is 
changed based on the engraftment by user) 
 
Morphometric Parameters 
 
Reporting level Details only 
 
Boundary  8-way Connected 
 
Put a check mark on the desired parameters listed: 
 
For our purpose, we used Object #, Units, Area, Perimeter, Diameter, Bin Classification, Minor 
Axis Diameter, and Elongation. 
 
B)  Choose “Bin” tab 
 
Add a new bin by clicking on   New 
Name the new bin as desire 
  
Criteria: 
   → Click on    ADD  
 
→ Choose   Area 
 
→ Scroll down and add >, <, ≤, ≥, based on myofibers area 
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 For Example:  
 
Area <   2000 
 
Area >   500 
  
These criteria will select large fibers between 500 to 2000 microns. 
 
Note: Click on    Remove   if there are any changes need to be made. Then, enter new criteria. 
Highlight the bin you need to get rid of and Click on    Delete   under Currently defined Bins. 
Check mark   √    “Include these Objects” only for the new bin created. Un-check for Default and 
delete   any other bins that may exist. 
 
Warning: The Include these Objects check box is an important check box to consider when 
making measurements with Northern Eclipse. In each new bin category, the criteria chosen can 
either be included or not included depending on this check box. Be careful when un-checking the 
Default Bin. It is possible to exclude any measurements from being made and if your system is a 
multi-user system, it may be wise to turn the Default Bin parameters back on or the next person 
using the system may not be getting the results they expect. 
 
C) Click on   Threshold   button in Toolbar.  
 
You will need to select a range of intensities that corresponds to the gray values in the object.  
The gray values can be seen in the main status bar by moving the mouse over the image before 
calling this function.  The display will change as you adjust the values, showing you the selected 
pixels in red/white and unselected pixels in cyan/black.  The range will be between 0 and 255 for 
8-bit images. In our case, the myofibers should have defined boundaries. If the threshold point is 
at low pixel intensity, red/white will flood the myofibers and the myofiber number will be 
underrepresented. If the threshold is at high pixel intensity, the connected components will 
decrease and we will not be representing small fibers. One way of dealing with composites with 
very different sizes of myofibers is to divide the analysis into two sets. First, set the criteria in 
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 your bin set up to count large fibers (Area >1000). Later change the criteria to measure the small 
myofibers (Area >100, <1000).  Note that the threshold levels will also require adjustment 
between the two measurements. 
 
D) Click on    Measure    button in Toolbar.  
 
The data will be created according to chosen parameters the in Data Result Window. By clicking 
on top of each parameter, the layout of the information can be changed so that the data can be 
listed in ascending or descending order. Each number can also be clicked individually and 
examined to see which myofiber corresponds to that number. In order to get rid of a measured 
myofiber, close the Data Result Window, go to the image, right click on the number or box on 
that fiber, and “Remove Object”. 
At last, 
 
E) Log to DDE if you are want to record the data to an excel spreadsheet. 
 
If Excel cannot be found, be sure it has been loaded onto the computer first. Also, be sure that 
Excel is run at least once prior to linking through DDE. Once the DDE link has been established, 
all subsequent data logging will use this connection. Book1 will then be launched, and the data 
will go to sheet1 (unless other wise specified). 
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